DOCSLIB.ORG

Legionellosis Investigation Guideline

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Legionellosis Investigation Guideline Legionellosis Investigation Guideline Contents CASE DEFINITION ............................................................................................................ 1 LABORATORY ANALYSIS .............................................................................................. 3 EPIDEMIOLOGY ............................................................................................................... 3 DISEASE OVERVIEW ....................................................................................................... 3 NOTIFICATION TO PUBLIC HEALTH AUTHORITIES ........................................... 5 INVESTIGATOR RESPONSIBILITIES .......................................................................... 6 STANDARD CASE INVESTIGATION AND CONTROL ............................................. 6 Case Investigation .......................................................................................................................................... 6 Contact Investigation ..................................................................................................................................... 7 Isolation, Work and Daycare Restrictions...................................................................................................... 7 Case Management .......................................................................................................................................... 7 Contact Management ..................................................................................................................................... 7 Environmental ................................................................................................................................................ 8 MANAGING SPECIAL SITUATIONS ............................................................................. 8 A. Outbreak Investigation: ......................................................................................................................... 8 DATA MANAGEMENT AND REPORTING .................................................................. 9 ADDITIONAL INFORMATION / REFERENCES ....................................................... 10 ATTACHMENTS .............................................................................................................. 10 Fact Sheet Attachments can be accessed through the Adobe Reader’s navigation panel for attachments. Throughout this document attachment links are indicated by this symbol ; when the link is activated in Adobe Reader it will open the attachments navigation panel. The link may not work when using PDF readers other than Adobe. Effective Date: 09/2009 Published Date: 01/06/2019 Current version: 01/2020 Last Updated: 11/07/2019 Revision History: Date Replaced Comments 01/2020 05/2018 New case definition for 2020. Investigations now cover a 14-day exposure period (increased from 10 days) and asks about more possible exposures. Updated Epidemiology, Disease Overview, Notification, Case Investigation, and Outbreak sections. 05/2018 07/2013 Updated Notification sections and Isolation, Work and Daycare Restrictions sections with updated regulations. 05/2014 05/2013 Edited notification section in association to travel/hotel related notifications. 05/2013 09/2009 Added notification section. Removed references to KS-EDSS (02/2012). Effective Date: 09/2009 Published Date: 01/06/2019 Current version: 01/2020 Revision History, Page 2 Legionellosis Disease Management and Investigative Guidelines CASE DEFINITION (CDC 2020) Clinical Description for Public Health Surveillance: Legionellosis is associated with three clinically and epidemiologically distinct illnesses: Legionnaires’ disease, Pontiac fever, or extrapulmonary legionellosis. • Legionnaires’ disease (LD): LD presents as pneumonia, diagnosed clinically and/or radiographically. Evidence of clinically compatible disease can be determined several ways: a) a clinical or radiographic diagnosis of pneumonia in the medical record OR b) if “pneumonia” is not recorded explicitly, a description of clinical symptoms that are consistent with a diagnosis of pneumonia Clinical symptoms of pneumonia may vary but must include acute onset of lower respiratory illness with fever and/or cough. Additional symptoms could include myalgia, shortness of breath, headache, malaise, chest discomfort, confusion, nausea, diarrhea, or abdominal pain. • Pontiac fever (PF): PF is a milder illness. While symptoms of PF could appear similar to those described for LD, there are distinguishing clinical features. PF does not present as pneumonia. It is less severe than LD, rarely requiring hospitalization. PF is self-limited, meaning it resolves without antibiotic treatment. Clinical symptoms may vary but must include acute symptom onset of one or more of the following: fever, chills, myalgia, malaise, headaches, fatigue, nausea and/or vomiting. • Extrapulmonary legionellosis (XPL): Legionella can cause disease at sites outside the lungs (for example, associated with endocarditis, wound infection, joint infection, graft infection). A diagnosis of extrapulmonary legionellosis is made when there is clinical evidence of disease at an extrapulmonary site and diagnostic testing indicates evidence of Legionella at that site. Laboratory Criteria for Case Classification: Confirmatory laboratory evidence: • Isolation of any Legionella organism from lower respiratory secretions, lung tissue, pleural fluid, or extrapulmonary site • Detection of any Legionella species from lower respiratory secretions, lung tissue, pleural fluid, or extrapulmonary site by a validated nucleic acid amplification test • Detection of Legionella pneumophila serogroup 1 antigen in urine using validated reagents • Fourfold or greater rise in specific serum antibody titer to Legionella pneumophila serogroup 1 using validated reagents Version 01/2020 Legionellosis, Page 1 Kansas Department of Health and Environment Investigation Guidelines Supportive laboratory evidence: • Fourfold or greater rise in antibody titer to specific species or serogroups of Legionella other than L. pneumophila serogroup 1 (e.g., L. micdadei, L. pneumophila serogroup 6) • Fourfold or greater rise in antibody titer to multiple species of Legionella using pooled antigens. • Detection of specific Legionella antigen or staining of the organism in lower respiratory secretions, lung tissue, pleural fluid, or extrapulmonary site associated with clinical disease by direct fluorescent antibody (DFA) staining, immunohistochemistry (IHC), or other similar method, using validated reagents Epidemiologic Linkage for Case Classification: 1) Epidemiologic link to a setting with a confirmed source of Legionella (e.g., positive environmental sampling result associated with a cruise ship, public accommodation, cooling tower, etc.), OR 2) Epidemiologic link to a setting with a suspected source of Legionella that is associated with at least one confirmed case. Case Classification: Confirmed Legionnaires’ disease (LD): A clinically compatible case of LD with confirmatory laboratory evidence for Legionella. Probable Legionnaires’ disease (LD): A clinically compatible case with an epidemiologic link during the 14 days before onset of symptoms. Suspect Legionnaires’ disease (LD): A clinically compatible case of LD with supportive laboratory evidence for Legionella. Confirmed Pontiac fever (PF): A clinically compatible case of PF with confirmatory laboratory evidence for Legionella. Probable Pontiac fever (PF): A clinically compatible case with an epidemiologic link during the 3 days before onset of symptoms. Suspect Pontiac fever (PF): A clinically compatible case of PF with supportive laboratory evidence for Legionella. Confirmed Extrapulmonary legionellosis (XPL): A clinically compatible case of XPL with confirmatory laboratory evidence of Legionella at an extrapulmonary site. Suspect Extrapulmonary legionellosis (XPL): A clinically compatible case of XPL with supportive laboratory evidence of Legionella at an extrapulmonary site. Version 01/2020 Legionellosis, Page 2 Kansas Department of Health and Environment Investigation Guidelines LABORATORY ANALYSIS Isolates are not required to be sent to the State Public Health Laboratory (KHEL); but they are equipped to confirm isolates of Legionella spp. Specimens for Legionella testing will be forwarded to the CDC only after prior clearance by the CDC Respiratory Diseases Branch. • When sending isolates to the state laboratory: Contact the laboratory at 785-620-1620. Use IDS (infectious disease shipper) for shipping. • When sending serology, urine, or pathologic specimens for testing at the CDC: Contact KDHE Epidemiology services for approval at 1-877-427-7317. An epidemiologist will request the information needed to verify an outbreak related case or if other special circumstances exist in which the CDC would need to assist. The epidemiologist will contact the Respiratory Disease Branch within the CDC Division of Bacterial Disease at 404-639-2215. After approval, specimen collection and delivery instructions will be given. Note: For serology, paired serum specimens taken at least 14 days apart are required. A single antibody titer at any level is not diagnostic for legionellosis. • For additional information, call (785) 296-1620. EPIDEMIOLOGY Legionellosis has a worldwide distribution. In the United States an estimated 8,000 - 18,000 cases occur annually; most are isolated and are not associated with outbreaks. Outbreaks usually occur in the summer and
Load more

Recommended publications
  • 2012 Case Definitions Infectious Disease
    Arizona Department of Health Services Case Definitions for Reportable Communicable Morbidities 2012 TABLE OF CONTENTS Definition of Terms Used in Case Classification .......................................................................................................... 6 Definition of Bi-national Case ............................................................................................................................................. 7 ------------------------------------------------------------------------------------------------------- ............................................... 7 AMEBIASIS ............................................................................................................................................................................. 8 ANTHRAX (β) ......................................................................................................................................................................... 9 ASEPTIC MENINGITIS (viral) ......................................................................................................................................... 11 BASIDIOBOLOMYCOSIS ................................................................................................................................................. 12 BOTULISM, FOODBORNE (β) ....................................................................................................................................... 13 BOTULISM, INFANT (β) ...................................................................................................................................................
    [Show full text]
  • Emerging Infectious Diseases Objectives What
    12/2/2015 EMERGING INFECTIOUS DISEASES What could be emerging in North Dakota? TRACY K. MILLER, PHD, MPH STATE EPIDEMIOLOGIST [email protected] OBJECTIVES 1. Identify new or re-emerging infections 2. Identify ways outside agencies can help the health department monitor for disease 3. Determine what education needs are available. 2 WHAT ARE "EMERGING" INFECTIOUS DISEASES? Infectious diseases whose incidence in humans has increased in the past two decades or threatens to increase in the near future have been defined as "emerging." These diseases, which respect no national boundaries, include: • New infections resulting from changes or evolution of existing organisms • Known infections spreading to new geographic areas or populations • Previously unrecognized infections appearing in areas undergoing ecologic transformation 3 1 12/2/2015 WHAT ARE RE-EMERGING INFECTIOUS DISEASES? Any condition, usually an infection, that had decreased in incidence in the global population and was brought under control through effective health care policy and improved living conditions, reached a nadir, and, more recently, began to resurge as a health problem due to changes in the health status of a susceptible population. 4 REPORTABLE CONDITIONS 5 CDC’S LIST OF EIDS • malaria • drug-resistant infections (antimicrobial resistance) • Marburg hemorrhagic fever • bovine spongiform encephalopathy (Mad cow disease) & variant Creutzfeldt-Jakob disease (vCJD) • measles • campylobacteriosis • meningitis • Chagas disease • monkeypox • cholera • MRSA (Methicillin Resistant
    [Show full text]
  • Report June 2
    COMMUNICABLE DISEASES • ISSN 1361 - 1887 Provisional Summary 2003 Northern Ireland Edition Vol 12 No 13 COMMUNICABLE DISEASES ISSN 1361 - 1887 Introduction This report summarises the main trends in communicable disease in Northern Ireland during 2003. It is primarily based on laboratory reports forward to CDSC (NI) and information supplied by Consultants in Communicable Disease Control. This is a more detailed annual summary than in previous years and replaces our annual report. The data for 2003 should be regarded as provisional to allow for late reporting of results and further typing of organisms. CDSC (NI) is extremely grateful to colleagues in Trusts and Boards for providing timely data and information on a wide range of infections and communicable disease issues. This summary can also be downloaded from our website http://www.cdscni.org.uk Contributing Laboratories Information Altnagelvin Mater Editorial Team: CDSC (NI) Antrim Musgrave Park Belfast City Hospital Belfast City Regional Mycology Dr Brian Smyth Lisburn Road, Belfast, BT9 7AB Belvoir Park Regional Virus Audrey Lynch N.Ireland Causeway Royal Victoria Dr Julie McCarroll Telephone: 028 9026 3765 Craigavon Tyrone County Dr Hilary Kennedy Fax: 028 9026 3511 Daisyhill Ulster Ruth Fox Email: [email protected] Erne Julie Boucher COMMUNICABLE DISEASES: Provisional Summary 1 Contents 1 Gastrointestinal Infections 3 Foodborne and Gastrointestinal outbreaks: 2003 2 Imported Infections 9 3 Human Brucellosis in Northern Ireland, 2003 13 4 Enhanced Surveillance of Influenza in Northern Ireland 15 5 Enhanced Surveillance of Meningococcal Disease 19 6 Enhanced Surveillance of Tuberculosis 23 7 Legionella Infections 27 8 Hepatitis 29 9 HIV and AIDS 33 10 Syphilis Outbreak in Northern Ireland 2001-2003 37 11 Childhood Vaccination Programme 41 Appendix 1 – Trends in Specific Reported Pathogens Appendix 2 – Notifications of Infections Diseases COMMUNICABLE DISEASES: Provisional Summary 2 1 Gastrointestinal infections Notifications of food poisoning increased steadily from1991 to 2000.
    [Show full text]
  • Middle East Respiratory Syndrome Coronavirus Update Legionnaires' Disease Outbreak in Shelby County
    WINTER IS NORO- ISSUE 1 VOLUME 7 2014 VIRUS SEASON ....... 2 ASSESSING DISPENS- ING ACCURACY FOR MEDICAL COUNTER- MEASURE EXCERCIS- ES .......................... 2 ONE HEALTH: WILD PIGS, HUNTERS AND BRUCELLOSIS……...3 WATCHING OUT FOR FLU ........................ 3 THE LIST OF REPORT- ABLE DISEASES AND EVENTS .................. 3 Tennessee TENNESSEE DEPARTMENT OF HEALTH COMMISSIONER JOHN J. DREYZEHNER, MD, MPH epi-news Legionnaires’ Disease Outbreak in Shelby County In June 2013, the Shelby County Health areas and to conduct environmental sam- Department received multiple reports of pling, testing and remediation using estab- Legionnaires’ disease among inpatients at lished methodologies. The investigators local hospitals. Health department epide- also initiated active surveillance for le- miologists quickly responded, conducting gionellosis and soon found four more cases detailed interviews with the patients using sharing this exposure. an interview form they had adapted with questions specific to Shelby County expo- Legionnaires’ disease is a form of commu- sures. nity-acquired pneumonia caused by Le- gionella species. A less severe form of Interviews with the first seven identified legionellosis is known as Pontiac fever. patients revealed that five of them had fre- Legionella bacteria are ubiquitous in the quented the same hot tub and steam room environment and thrive in warm, manmade conditions are predisposing factors. Most in a fitness center within two to ten days water systems. People can become infected cases occur sporadically
    [Show full text]
  • Copyrighted Material
    INDEX A American hemorrhagic fevers: Antibiotic action; Drug resistance; Α-dystroglycan, 301 Argentine, 16–17, 35, 279–280; Immune system; specifi c disease Abrus precatorius, 689 Bolivian, 277, 280, 287–288; Antiviral agents: AZT (zidovudine), Acid-fast bacteria, 212 Brazilian, 277, 281; overview of, 13, 32, 38, 48, 340–341, 355, 356; Active Bacterial Core (ABCs) 274, 274–279, 282–286; treatment, blocking synthesis of bacterial surveillance, 240 prevention, surveillance of, 275, RNA, 47; categories of HIV, 356; Active immunization, 465 287–289; Venezuelan, 277, 280–281 dengue fever, DHF, and DSS, 327– Acute glomerulonephritis, 119, 121, 126 Amoeba histolytica, 34 328; description of, 32; HAART, Acute Q fever, 15 Anaplasma phagocytophilum, 36, 76, 77, 48, 356–357, 382; hepatitis C virus Adaptive immunity, 40–42 84, 85, 86, 89, 90, 640–641, 645 (HCV), 391, 402–403; HHV-8 Adenocarcinoma of the lower Anaplasmosis, 552 and KS treatment using, 380–382; esophagus, 167–168 Andes virus, 442 SARS, 466–467. See also Interferons Adenovirus infection, 646–647 Anemia, 176, 528 Arenaviridae, 300 Aedes aegypti mosquito, 318, 322, Angiotensin-converting enzyme 2 Argentine hemorrhagic fever, 16–17, 328–329 (ACE-2), 463–464 35, 279–280 Aedes albopictus mosquito, 318, 322–323 Anopheles mosquitoes, 35, 525, 526, 537 Artemisinin, 535 Age-related immune system defects, Anthrax, 15, 670, 674–676 “Asian Flu” pandemic (type H2N2) 639–640, 642 Antibiotic action, 226, 228–229, 235– [1957], 413 Agglutination, 44 237. See also Antimicrobial agents; Aspergillus fungi,
    [Show full text]
  • INFECTIOUS DISEASES of ETHIOPIA Infectious Diseases of Ethiopia - 2011 Edition
    INFECTIOUS DISEASES OF ETHIOPIA Infectious Diseases of Ethiopia - 2011 edition Infectious Diseases of Ethiopia - 2011 edition Stephen Berger, MD Copyright © 2011 by GIDEON Informatics, Inc. All rights reserved. Published by GIDEON Informatics, Inc, Los Angeles, California, USA. www.gideononline.com Cover design by GIDEON Informatics, Inc No part of this book may be reproduced or transmitted in any form or by any means without written permission from the publisher. Contact GIDEON Informatics at [email protected]. ISBN-13: 978-1-61755-068-3 ISBN-10: 1-61755-068-X Visit http://www.gideononline.com/ebooks/ for the up to date list of GIDEON ebooks. DISCLAIMER: Publisher assumes no liability to patients with respect to the actions of physicians, health care facilities and other users, and is not responsible for any injury, death or damage resulting from the use, misuse or interpretation of information obtained through this book. Therapeutic options listed are limited to published studies and reviews. Therapy should not be undertaken without a thorough assessment of the indications, contraindications and side effects of any prospective drug or intervention. Furthermore, the data for the book are largely derived from incidence and prevalence statistics whose accuracy will vary widely for individual diseases and countries. Changes in endemicity, incidence, and drugs of choice may occur. The list of drugs, infectious diseases and even country names will vary with time. Scope of Content: Disease designations may reflect a specific pathogen (ie, Adenovirus infection), generic pathology (Pneumonia – bacterial) or etiologic grouping(Coltiviruses – Old world). Such classification reflects the clinical approach to disease allocation in the Infectious Diseases Module of the GIDEON web application.
    [Show full text]
  • Legionellosis Investigation Form
    LEGIONELLOSIS INVESTIGATION FORM BASIC DEMOGRAPHIC DATA Last Name:________________________________ First Name:_______________________________ Middle Name:________________________ DOB: __ __ / __ __ /__ __ __ __ Age: _______ years months Current Sex: Female Male Unknown Is the patient deceased? No Unknown Yes Date of Death: __ __ / __ __ /__ __ __ __ Street Address 1:_____________________________________________________________ Street Address 2:______________________________ City:_______________________________________ State:_______ Zip Code:_______________ County:_______________________________ Home Phone: (__ __ __) ‐ __ __ __ ‐ __ __ __ __ Cell Phone: (__ __ __) ‐ __ __ __ ‐ __ __ __ __ Work Phone: (__ __ __) ‐ __ __ __ ‐ __ __ __ __ Ext. _______ Ethnicity: Hispanic or Latino Not Hispanic or Latino Unknown Race: American Indian/Alaska Native Asian Black/African American Native Hawaiian/Other Pacific Islander White Unknown INVESTIGATION SUMMARY Investigation Start Date: __ __ / __ __ /__ __ __ __ Investigation Status: Open Closed Investigator:__________________________________ REPORTING SOURCE Date of Report: __ __ / __ __ /__ __ __ __ Reporting Source:_______________________________________________________________________ CLINICAL Physician’s Name:_______________________________________________________ Phone Number: (__ __ __) ‐ __ __ __ ‐ __ __ __ __ Ext. _______ Was patient hospitalized for this illness? No Unknown Yes If yes: Hospital Name:_______________________________________________ Admission Date: __ __
    [Show full text]
  • Biological Role of Legionella Pneumophila Lipopolysaccharide
    Volume 4- Issue 1: 2018 DOI: 10.26717/BJSTR.2018.04.001003 Marta Palusinska Szysz. Biomed J Sci & Tech Res ISSN: 2574-1241 Mini Review Open Access Biological Role of Legionella Pneumophila lipopolysaccharide Marta Palusińska Szysz*1, Agata Wołczańska2 and Elżbieta Chmiel1 1Department of Genetics and Microbiology, Maria Curie-Sklodowska University, Poland 2Department of Botany and Mycology, Maria Curie-Sklodowska University, Poland Received: April 16, 2018; Published: April 26, 2018 *Corresponding author: Marta Palusinska Szysz, Faculty of Biology and Biotechnology, Institute of Microbiology and Biotechnology, Department of Genetics and Microbiology, Maria Curie-Sklodowska University, Akademicka 19 St., 20-033 Lublin, Poland Abstract bacteria which contributes to the cell surface properties in an exceptionally important way. The chemical structure of L. pneumophila LPS is differentThe lipopolysaccharidefrom that of the endotoxins (LPS) localized of other in Gram-negativethe outer membrane bacteria, is the despite predominant the similar molecule structure. on theDue cell to itssurface complex of Legionella structure pneumophila and function as well as immunochemical and antigen variability, the L. pneumophila LPS plays an important role in the interaction with the host cell. Introduction Legionella bacteria incapable of causing pneumonia in the affected Legionella pneumophila is an aquatic pathogen that is ubiquitously found in nature, both in anthropogenic structures infection is pneumonia, which does not require hospitalization. and in environmental waters as parasites of free living protozoa. host [8]. The most common clinical manifestation of Legionella Fatal courses of the disease occur when the bacteria disseminate In evolution with protozoa, L. pneumophila acquired a rare ability deeper into the lung. among microorganisms to infect macrophages owing to their The infection progresses from bronchopneumonia to lobar as one of the three most common causes of severe community- pneumonia.
    [Show full text]
  • INFECTIOUS DISEASES of HAITI Free
    INFECTIOUS DISEASES OF HAITI Free. Promotional use only - not for resale. Infectious Diseases of Haiti - 2010 edition Infectious Diseases of Haiti - 2010 edition Copyright © 2010 by GIDEON Informatics, Inc. All rights reserved. Published by GIDEON Informatics, Inc, Los Angeles, California, USA. www.gideononline.com Cover design by GIDEON Informatics, Inc No part of this book may be reproduced or transmitted in any form or by any means without written permission from the publisher. Contact GIDEON Informatics at [email protected]. ISBN-13: 978-1-61755-090-4 ISBN-10: 1-61755-090-6 Visit http://www.gideononline.com/ebooks/ for the up to date list of GIDEON ebooks. DISCLAIMER: Publisher assumes no liability to patients with respect to the actions of physicians, health care facilities and other users, and is not responsible for any injury, death or damage resulting from the use, misuse or interpretation of information obtained through this book. Therapeutic options listed are limited to published studies and reviews. Therapy should not be undertaken without a thorough assessment of the indications, contraindications and side effects of any prospective drug or intervention. Furthermore, the data for the book are largely derived from incidence and prevalence statistics whose accuracy will vary widely for individual diseases and countries. Changes in endemicity, incidence, and drugs of choice may occur. The list of drugs, infectious diseases and even country names will vary with time. © 2010 GIDEON Informatics, Inc. www.gideononline.com All Rights Reserved. Page 2 of 314 Free. Promotional use only - not for resale. Infectious Diseases of Haiti - 2010 edition Introduction: The GIDEON e-book series Infectious Diseases of Haiti is one in a series of GIDEON ebooks which summarize the status of individual infectious diseases, in every country of the world.
    [Show full text]
  • Legionnaires• Disease: Clinical Differentiation from Typical And
    Legionnaires’ Disease: Clinical Differentiation from Typical and Other Atypical Pneumonias a,b, Burke A. Cunha, MD, MACP * KEYWORDS Clinical syndromic diagnosis Relative bradycardia Ferritin levels Hypophosphatemia HISTORY An outbreak of a severe respiratory illness occurred in Washington, DC, in 1965 and another in Pontiac, Michigan, in 1968. Despite extensive investigations following these outbreaks, no explanation or causative organism was found. In July 1976 in Philadel- phia, Pennsylvania, an outbreak of a severe respiratory illness occurred at an Amer- ican Legion convention. The US Centers for Disease Control and Prevention (CDC) conducted an extensive epidemiologic and microbiologic investigation to determine the cause of the outbreak. Dr Ernest Campbell of Bloomsburg, Pennsylvania, was the first to recognize the relationship between the American Legion convention in 3 of his patients who attended the convention and who had a similar febrile respiratory infection. Six months after the onset of the outbreak, a gram-negative organism was isolated from autopsied lung tissue. Dr McDade, using culture media used for rickettsial organisms, isolated the gram-negative organism later called Legionella. The isolate was believed to be the causative agent of the respiratory infection because antibodies to Legionella were detected in infected survivors. Subsequently, CDC investigators realized the antecedent outbreaks of febrile illness in Philadelphia and in Pontiac were caused by the same organism. They later demonstrated increased Legionella titers in survivors’ stored sera. The same organism was responsible for the pneumonias that occurred after the American Legionnaires’ Convention in Philadelphia in 1976. a Infectious Disease Division, Winthrop-University Hospital, 259 First Street, Mineola, Long Island, NY 11501, USA b State University of New York School of Medicine, Stony Brook, NY, USA * Infectious Disease Division, Winthrop-University Hospital, 259 First Street, Mineola, Long Island, NY 11501.
    [Show full text]
  • Healthy Brookline Volume
    HEALTHY BROOKLINE VOLUME XVI Communicable Diseases in Brookline Brookline Department of Public Health 2015 ACKNOWLEDGEMENTS This report was prepared by Janelle Mellor, MPH, with support from Natalie Miller, MPH, Barbara Westley, RN, and Lynne Karsten, MPH, under the direction of Alan Balsam, PhD, MPH, Director of Public Health and Human Services in Brookline. Thanks are also due to the Division Directors at the Brookline Department of Public Health for their support and input: Lynne Karsten, MPH Patrick Maloney, MPAH Mary Minott, LICSW Patricia Norling Gloria Rudisch, MD, MPH Dawn Sibor, MEd Barbara Westley, RN A special thanks to the Brookline Advisory Council on Public Health Bruce Cohen, PhD-Chair Roberta Gianfortoni, MA Milly Krakow, PhD Cheryl Lefman, MA Patricia Maher, RN/NP, MA/MA Anthony Schlaff, MD, MPH Support and data were also provided by: Susan Soliva, MPH, Massachusetts Department of Public Health The Healthy Brookline Chartbooks represent a partnership with a variety of funding sources: Beth Israel Deaconess Medical Center Brigham & Women’s Hospital Children’s Hospital Farnsworth Trust Tufts Medical Center St. Elizabeth’s Medical Center Blue Cross Blue Shield of Massachusetts Brookline Community Foundation Harvard Pilgrim Health Care Foundation Tufts Health Plan We thank them all for their generous support. Table of Contents Section 1: Communicable Disease Surveillance and Reporting .................................................................. 1 Surveillance and Reporting ......................................................................................................................
    [Show full text]
  • 2008 Indiana Report of Infectious Diseases
    2008 Indiana Report of Infectious Diseases All incidence rates throughout the report are per 100,000 population based on the U.S. Census Bureau’s population data as of July 1, 2008. Data for counties reporting fewer than five disease cases are not included to protect the confidentiality of the cases. Data for fewer than 20 reported disease cases are considered statistically unstable. References American Academy of Pediatrics. In: Pickering LK, Baker CJ, Long SS, McMillan JA, eds. Red Book: 2006 Report of the Committee on Infectious Diseases. 27th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2006. Centers for Disease Control and Prevention. Manual for the surveillance of vaccine-preventable diseases. Centers for Disease Control and Prevention, Atlanta, GA, 2008. Centers for Disease Control and Prevention. Epidemiology and Prevention of Vaccine-Preventable Diseases. Atkinson W, Wolfe S, Hamborsky J, McIntyre L, eds. 11th ed. Washington DC: Public Health Foundation, 2009. Heyman, D.L. (2008). Control of Communicable Diseases Manual (19th ed.). American Public Health Association. Websites www.cdc.gov Animal Bites Measles Anthrax Meningitis (aseptic) Arboviral Encephalitis Meningococcal Disease Babesiosis Mumps Botulism Pertussis Brucellosis Plague Campylobacteriosis Pneumococcal Disease Cholera Poliomyelitis Cryptosporidiosis Psittacosis Cyclosporiasis Q Fever Dengue Fever and Dengue Hemorrhagic Fever Rabies Diphtheria Rocky Mountain Spotted Fever Ehrlichiosis Rubella Escherichia coli O157:H7 Salmonellosis Haemophilus influenzae
    [Show full text]